Skip to main content
Clinical Trials/NCT05931562
NCT05931562
Recruiting
Not Applicable

An Interventional Study on the Association Between Diet, Cognitive Function, Stress and the Gut Microbiota in Healthy Volunteers.

University College Cork1 site in 1 country200 target enrollmentJuly 14, 2022
ConditionsHealthy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy
Sponsor
University College Cork
Enrollment
200
Locations
1
Primary Endpoint
Responses to acute stress: hypothalamic-pituitary-adrenal axis activity
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study aims to investigate the effects of an 8-week dietary intervention on cognitive function, stress, and the gut microbiota in healthy adults with low fibre intake.

Detailed Description

The gut microbiota communicates bidirectionally with the brain via the microbiota-gut-brain axis to influence various aspects of human physiology, including host metabolism, immune function, behaviour, and cognition. Diet is a key modulator of the microbial composition, suggesting that the microbiota could explain the association between poor nutrition and decreasing health of the population. Dietary fibre is the main energy source for the gut microbiota and fundamentally impacts its composition and function. The microbiota-gut-brain axis has been proposed to mediate some of the effects of dietary fibre on the brain, for example through microbial metabolites (e.g., short-chain fatty acids (SCFA)), regulation of the immune system, and the microbial impact on gut hormones and neurotransmitters. Similarly, intake of fermented foods is positively associated with cognitive health and has been shown to alter the microbiota composition and function and exert an anti-inflammatory effect. However, no studies to date have examined the singular and combined effects of fermented and fibrous foods on the gut microbiota, cognition, and emotion. The present study aims to determine the role of diet on the microbiota-gut-brain axis and mental health. Using a randomized-controlled, parallel, single-blinded design, participants consuming a habitually low fibre diet (N=200) will undergo an 8-week dietary intervention. Participants will receive one of four diets (n=50 in each group): high fibre (aim 24-35 grams/day), fermented foods (aim 4-6 portions/day), combined diet of fermented foods and high fibre (aim 25-30g/day of fibre and 3-4 servings/day of fermented foods) or control (dietary education according to national Irish guidelines). Cognitive, psychological, and biological measures will be compared at baseline and endpoint. During the intervention period, individuals will provide repeated faecal samples to assess temporal microbial changes.

Registry
clinicaltrials.gov
Start Date
July 14, 2022
End Date
July 2026
Last Updated
last year
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Be able to give written informed consent.
  • Be between 18 and 50 years of age.
  • Have a body mass index (BMI) between 18.5-29.9 Kg/m
  • Be in generally good health as determined by the investigator.

Exclusion Criteria

  • Are less than 18 and greater than 50 years of age.
  • Have a BMI below 18.5 or above 29.9 Kg/m
  • Have a significant acute or chronic coexisting illness \[cardiovascular, gastrointestinal (GI) \[to include functional GI disorders, inflammatory bowel disease, coeliac disease, lactose intolerance, food allergies\], immunological, psychiatric \[to include formal or as determined by MINI Psychiatric interview, diagnosis of current major depression, anxiety disorder, bipolar spectrum disorder, schizophrenia, other DSM-IV Axis I disorder\], neurodevelopmental disorders, immunological, metabolic disorders \[to include type I or II diabetes\], or any condition which contraindicates, in the investigators judgement, entry to the study,
  • Have a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk, or confound the interpretation of the study results; all psychoactive medications \[to include anxiolytics, antipsychotics, antidepressants, anticonvulsants, centrally acting corticosteroids, and opioid pain relievers), laxatives, enemas, antibiotics, anti-coagulants, over-the counter non-steroidal anti-inflammatories (NSAIDS). Subjects should have a wash-out period of 4 weeks.
  • Current prebiotic or probiotic supplement use (a wash-out period of 4 weeks after cessation will allow entry to the study).
  • Females who are peri-menopausal, menopausal or post-menopausal.
  • Females who are pregnant or planning a pregnancy, or lactating.
  • Participants who are not fluent in English.
  • Are colour blind.
  • Have dyslexia or dyscalculia.

Outcomes

Primary Outcomes

Responses to acute stress: hypothalamic-pituitary-adrenal axis activity

Time Frame: Change from baseline at 8 weeks

Cortisol from saliva samples

Trait stress/mood: self-report

Time Frame: Change from baseline at 8 weeks

self-report questionnaires

Responses to acute stress: self-report

Time Frame: Change from baseline at 8 weeks

Self-report questionnaires

Responses to acute stress: sympathetic-adrenal-medullary pathway activity

Time Frame: Change from baseline at 8 weeks

Galvanic skin response taken from the skin on the hand

Trait stress/mood: hypothalamic-pituitary-adrenal axis activity

Time Frame: Change from baseline at 8 weeks

Cortisol from saliva samples

Secondary Outcomes

  • Cognitive performance: decision making(Change from baseline at 8 weeks)
  • Inflammation(Change from baseline at 8 weeks)
  • Microbial and host metabolomics(Change from baseline at 8 weeks)
  • Cognitive performance: emotional inhibition(Change from baseline at 8 weeks)
  • Cognitive performance: social cognition(Change from baseline at 8 weeks)
  • Cognitive performance: working memory(Change from baseline at 8 weeks)
  • Cognitive performance: sustained attention(Change from baseline at 8 weeks)
  • Cognitive performance: affective perceptual bias(Change from baseline at 8 weeks)
  • Cognitive performance: episodic memory(Change from baseline at 8 weeks)
  • Cognitive performance: visual pattern recognition memory(Change from baseline at 8 weeks)
  • Cognitive performance: cognitive flexibility(Change from baseline at 8 weeks)
  • Microbiota composition and function(Change from baseline at 8 weeks)

Study Sites (1)

Loading locations...

Similar Trials